The world is now aging rapidly in Asian countries and developed countries. Dementia will be a risk for social and economic activities in these countries. Nowadays there are symptomatic therapies and no causal therapy against dementia. Preventing dementia is a key role for aging societies to keep social activities. Mild cognitive impairment (MCI) is reversible impairment such as frequent forgetfulness, lack of seasonal sense, disorientation, sociability and etc. The people having MCI are ordinary people living as usual but it is said that a half of them would be dementia patient in near future. Therefore, how tomanage people having MCI and prevent dementia is a global issue proposed by G7 Ise-Shima Summit 2016. Here, we developed Artificial Intelligence (AI) technology detecting cognitive impairment of elderly people from functional near infra-red spectroscopy (fNIRS) signals during verbal interaction. This technology is able to use world-widely because the determination is composed of monitoring cerebral blood flow activation measured by portable fNIRS . Our technology evaluates cognitive decline with automatically determining the clinical diagnostic group: cognitively normal (CN), MCI and mild Alzheimer's dementia (AD). Our technology is thereby able to perform cognitive dysfunction assessments that are suitable for early stage screening of large numbers of elderly people. Weareseekinggovernmental partners or public utilities organizations in Asia as we aim to have our technology tobe used world-wide in the near future.
The data of cerebral blood flow signalsmonitored on a portable functional near infra-red spectroscopy (fNIRS) are independent of the communication with any languagessuch asGerman, French, Chinese, Englishand so on. We can determine cognitive decline and screen the high risk group of of Alzheimer's type dementia. This high risk group could be recovered from by lifestyle improvements and training.
Ourtechnology can be utilized ascognitive dysfunction assessments that are suitable for early stage screening of large numbers of elderly people, especially detecting Mild cognitive impairment.The device can be marketed as a health care ICT device, notforhospital usage.It enables us to provide this as a consumer product.
This device can easily check cognitive decline "anytime, anywhere", not at hospitals.